---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-009738"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:50:41.441691+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Karyopharm reports prelim FY2025 total revenue ~$145M; cash ~$64M; Phase 3 myelofibrosis data due March 2026

## Summary
- Preliminary total revenue for 2025 ~$145M; Q4 2025 ~$33M. U.S. XPOVIO net product revenue 2025 ~$115M; Q4 ~$32M.
- Cash and investments as of Dec 31, 2025 ~$64M; liquidity expected to fund operations into Q2 2026.
- Top-line data from Phase 3 SENTRY trial in myelofibrosis expected in March 2026; XPORT-EC-042 endometrial cancer data due mid-2026.
- Completed strategic financing transactions to extend cash runway beyond SENTRY readout.
- Global patient access expanded: selinexor approved in >50 countries; reimbursement in Spain and China.

## SEC filing metadata
- accession: 0001193125-26-009738
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/0001193125-26-009738-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312526009738/kpti-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-009738
- JSON: https://secwatch.observer/filing/0001193125-26-009738.json
- Plain text: https://secwatch.observer/filing/0001193125-26-009738.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.